TCT-685 Costs Of Peri-Procedural Complications Among Patients Treated With A Self-Expanding Transcatheter Aortic Valve Prosthesis: Results From The CoreValve US Pivotal Extreme Risk Study
Suzanne J. Baron(Harvard University), David J. Cohen(Baim Institute for Clinical Research), Suzanne V. Arnold(Saint Luke's Health System), David C. Adams(Icahn School of Medicine at Mount Sinai), Tanvir Bajwa(Aurora Health Care), Daniel O’Hair(UPMC Health System), Jeffrey J. Popma(Cardiovascular Research Foundation), Elizabeth A. Magnuson(Saint Luke's Health System), Timothy Byrne, Matthew R. Reynolds(Harvard University Press), Yang Lei(Emory University)
Cited by 1
Related Papers
Clinical End Points in Coronary Stent Trials
|Circulation|2007|5.4k
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
|New England Journal of Medicine|2016|5.1k
Transcatheter Aortic-Valve Replacement with a Balloon-Expandable Valve in Low-Risk Patients
|New England Journal of Medicine|2019|4.8k
Transcatheter Aortic-Valve Replacement with a Self-Expanding Valve in Low-Risk Patients
|New England Journal of Medicine|2019|3.6k
Stenting versus Endarterectomy for Treatment of Carotid-Artery Stenosis
|New England Journal of Medicine|2010|3k